Yarrow Supercritical Extract Ameliorates the Metabolic Stress in a Model of Obesity Induced by High-Fat Diet
Tóm tắt
Nowadays, obesity and its associated metabolic disorders, including diabetes, metabolic syndrome, cardiovascular disease, or cancer, continue to be a health epidemic in westernized societies, and there is an increased necessity to explore anti-obesity therapies including pharmaceutical and nutraceutical compounds. Considerable attention has been placed on the identification of bioactive compounds from natural sources to manage the metabolic stress associated with obesity. In a previous work, we have demonstrated that a CO2 supercritical fluid extract from yarrow (Yarrow SFE), downregulates the expression of the lipogenic master regulator SREBF1 and its downstream molecular targets FASN and SCD in a tumoral context. Since obesity and diabetes are strongly considered high-risk factors for cancer development, herein, we aimed to investigate the potential therapeutic role of Yarrow SFE in the metabolic stress induced after a high-fat diet in mice. For this purpose, 32 C57BL/6 mice were distributed in four groups according to their diets: standard diet (SD); SD supplemented with Yarrow SFE (SD + Yarrow); high-fat diet (HFD); and HFD supplemented with Yarrow SFE (HFD + Yarrow). Fasting glycemia, insulin levels, homeostasis model assessment for insulin resistance (HOMA-IR), lipid profile, gene expression, and lipid content of liver and adipose tissues were analyzed after three months of treatment. Results indicate improved fasting glucose levels in plasma, enhanced insulin sensitivity, and diminished hypercholesterolemia in the HFD + Yarrow group compared to the HFD group. Mechanistically, Yarrow SFE protects liver from steatosis after the HFD challenge by augmenting the adipose tissue buffering capacity of the circulating plasma glucose.
Từ khóa
Tài liệu tham khảo
Grundy, 2016, Metabolic syndrome update, Trends Cardiovasc. Med., 26, 364, 10.1016/j.tcm.2015.10.004
Gallagher, 2015, Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality, Physiol. Rev., 95, 727, 10.1152/physrev.00030.2014
Kahn, 2006, Mechanisms linking obesity to insulin resistance and type 2 diabetes, Nature, 444, 840, 10.1038/nature05482
Ye, 2013, Mechanisms of insulin resistance in obesity, Front. Med. China, 7, 14, 10.1007/s11684-013-0262-6
Kahn, 2000, On diabetes: Insulin resistance Obesity and insulin resistance, J. Clin. Investig., 106, 473, 10.1172/JCI10842
Schalkwijk, 2013, Obesity-associated low-grade inflammation in type 2 diabetes mellitus: Causes and consequences, Neth. J. Med., 71, 174
Davies, 2018, Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 61, 2461, 10.1007/s00125-018-4729-5
American Diabetes Association (2018). Obesity management for the treatment of type 2 diabetes: Standards of medical care in diabetes—2018. Diabetes Care, 41, S65–S72.
Cicero, 2016, Role of phytochemicals in the management of metabolic syndrome, Phytomedicine, 23, 1134, 10.1016/j.phymed.2015.11.009
Saad, B., Zaid, H., Shanak, S., and Kadan, S. (2017). Anti-Diabetes and Anti-Obesity Medicinal Plants and Phytochemicals: Safety, Efficacy, and Action Mechanisms, Springer.
2011, Dietary phytochemicals and their potential effects on obesity: A review, Pharmacol. Res., 64, 438, 10.1016/j.phrs.2011.07.004
Teoh, 2018, Phytochemicals and their effective role in the treatment of diabetes mellitus: A short review, Phytochem. Rev., 17, 1111, 10.1007/s11101-018-9575-z
Zhao, 2018, Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus, Crit. Rev. Food Sci. Nutr., 59, 830, 10.1080/10408398.2018.1501658
Mouhid, L., Gomez de Cedron, M., Garcia-Carrascosa, E., Reglero, G., Fornari, T., and Ramirez de Molina, A. (2019). Yarrow supercritical extract exerts antitumoral properties by targeting lipid metabolism in pancreatic cancer. PLoS ONE, 14.
Ilic, 2016, Epidemiology of pancreatic cancer, World J. Gastroenterol., 22, 9694, 10.3748/wjg.v22.i44.9694
Mouhid, 2017, Biological Activities of Asteraceae (Achillea millefolium and Calendula officinalis) and Lamiaceae (Melissa officinalis and Origanum majorana) Plant Extracts, Plant Foods Hum. Nutr., 72, 96, 10.1007/s11130-016-0596-8
Singh, 2010, Surrogate markers of insulin resistance: A review, World J. Diabetes, 1, 36, 10.4239/wjd.v1.i2.36
Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method, Methods, 25, 402, 10.1006/meth.2001.1262
Wang, 2011, New insights into the mechanism of low high-density lipoprotein cholesterol in obesity, Lipids Health Dis., 10, 176, 10.1186/1476-511X-10-176
Greenberg, 2006, Obesity and the role of adipose tissue in inflammation and metabolism, Am. J. Clin. Nutr., 83, 461S, 10.1093/ajcn/83.2.461S
Saltiel, 2001, Insulin signalling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a
Nguyen, 2008, Liver lipid metabolism, J. Anim. Physiol. Anim. Nutr. (Berl.), 92, 272, 10.1111/j.1439-0396.2007.00752.x
Goedeke, 2019, Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes, Annu. Rev. Pharmacol. Toxicol., 59, 65, 10.1146/annurev-pharmtox-010716-104727
Reaven, 2017, Pathophysiology of insulin resistance in human disease, Physiol. Rev., 75, 473, 10.1152/physrev.1995.75.3.473
Shepherd, 1999, Mechanisms of disease—Glucose transporters and insulin action—Implications for insulin resistance and diabetes mellitus, N. Engl. J. Med., 341, 248, 10.1056/NEJM199907223410406
Smith, 2016, Adipose tissue regulates insulin sensitivity: Role of adipogenesis, de novo lipogenesis and novel lipids, J. Intern. Med., 280, 465, 10.1111/joim.12540
Morigny, 2016, Adipocyte lipolysis and insulin resistance, Biochimie, 125, 259, 10.1016/j.biochi.2015.10.024
Boizard, 1998, Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors, J. Biol. Chem., 273, 29164, 10.1074/jbc.273.44.29164
Sekiya, 2007, SREBP-1-independent regulation of lipogenic gene expression in adipocytes, J. Lipid Res., 48, 1581, 10.1194/jlr.M700033-JLR200
Carobio, 2013, Adaptive Changes of the Insig1/SREBP1/SCD1 Set Point Help Adipose Tissue to Cope With Increased Storage Demands of Obesity, Diabetes, 62, 3697, 10.2337/db12-1748
Horton, 2002, SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver, J. Clin. Investig., 109, 1125, 10.1172/JCI0215593
Schugar, R.C., Huang, X., Moll, A.R., Brunt, E.M., and Crawford, P.A. (2013). Role of Choline Deficiency in the Fatty Liver Phenotype of Mice Fed a Low Protein, Very Low Carbohydrate Ketogenic Diet. PLoS ONE, 8.
Corbin, 2012, Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression, Curr. Opin. Gastroenterol., 28, 159, 10.1097/MOG.0b013e32834e7b4b